Nurix Therapeutics, Inc.
NRIX · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Market Cap | $1,484,029 | $337,982 | $602,253 | $1,236,245 |
| - Cash | $109,997 | $54,627 | $64,474 | $80,506 |
| + Debt | $28,303 | $30,614 | $11,964 | $13,036 |
| Enterprise Value | $1,402,335 | $313,969 | $549,743 | $1,168,775 |
| Revenue | $54,549 | $76,987 | $38,627 | $29,750 |
| % Growth | -29.1% | 99.3% | 29.8% | – |
| Gross Profit | -$167,083 | -$112,161 | -$145,870 | -$86,684 |
| % Margin | -306.3% | -145.7% | -377.6% | -291.4% |
| EBITDA | -$205,009 | -$148,930 | -$179,718 | -$115,896 |
| % Margin | -375.8% | -193.4% | -465.3% | -389.6% |
| Net Income | -$193,569 | -$143,948 | -$180,360 | -$117,194 |
| % Margin | -354.9% | -187% | -466.9% | -393.9% |
| EPS Diluted | -2.88 | -2.65 | -3.71 | -2.73 |
| % Growth | -8.7% | 28.6% | -35.9% | – |
| Operating Cash Flow | -$172,584 | -$81,365 | -$159,807 | -$84,365 |
| Capital Expenditures | -$9,273 | -$8,401 | -$12,244 | -$5,661 |
| Free Cash Flow | -$181,857 | -$89,766 | -$172,051 | -$90,026 |